Tdap 백신은 아다셀(Adacel)과 부스트릭스(Boostrix)가 있습니다.
Composition of and indications for diphtheria, tetanus, and pertussis vaccines for infants, children, and adolescents
|
Vaccine |
Diphtheria toxoid (Lf units) |
Tetanus toxoid (Lf units) |
Pertussis antigens |
Approved doses and age groups |
|
Vaccines for children ≥7 years, adolescents, and adults |
||||
|
Td |
2 |
2 to 5 |
None |
Booster dose (≥7 years) |
|
Tdap |
||||
|
Adacel |
2 |
5 |
PT (2.5 mcg) FHA (5 mcg) PERT (3 mcg) FIM (5 mcg) |
Booster dose (10 through 64 years)¶ |
|
Boostrix |
2.5 |
5 |
PT (8 mcg) FHA (8 mcg) PERT (2.5 mcg) |
≥10 years |
¶ The Advisory Committee on Immunization Practices recommends off-label use of Tdap vaccine for children age 7 to 10 years who are not fully vaccinated against pertussis.[1]
아다셀은 사노피 파스퇴르, 부스트릭스는 GSK 제품이며
아다셀은 한독약품 판매, 부스트릭스는 유한양행 판매입니다.
REF. UpToDate 2019.06.12
'감염내과 > 예방접종' 카테고리의 다른 글
| Comparison of serotypes in pneumococcal vaccines (0) | 2019.08.12 |
|---|---|
| UpToDate recommendations* for the administration of pneumococcal vaccines (PCV13, PPSV23) in adult (0) | 2019.08.12 |
| 성인 파상풍 예방접종, Routine adult immunization of Tdap or Td (0) | 2019.06.12 |
| 장티푸스 백신, Typhoid vaccine [2] 작용 기전과 효능 (0) | 2019.05.27 |
| 장티푸스 백신, Typhoid vaccine [1] 용량과 적응증 (0) | 2019.05.27 |
